Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.510
-0.220 (-8.06%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.

The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia.

It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia.

The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Annovis Bio, Inc.
Annovis Bio logo
CountryUnited States
Founded2008
IPO DateJan 29, 2020
IndustryBiotechnology
SectorHealthcare
Employees15
CEOMaria Maccecchini

Contact Details

Address:
101 Lindenwood Drive, Suite 225
Malvern, Pennsylvania 19355
United States
Phone484 875 3192
Websiteannovisbio.com

Stock Details

Ticker SymbolANVS
ExchangeNYSE
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$6.00
CIK Code0001477845
CUSIP Number03615A108
ISIN NumberUS03615A1088
Employer ID26-2540421
SIC Code2834

Key Executives

NamePosition
Dr. Maria L. Maccecchini Ph.D.Founder, Chief Executive Officer, President and Executive Director
Andrew WalshPrincipal Financial Officer
Dr. Cheng Fang Ph.D.Senior Vice President of Research and Development
Eve M. Damiano M.S., RACSenior Vice President of Regulatory Operations
Melissa GainesSenior Vice President of Clinical Operations
Blake Jensen M.B.A.Head of Quality
Hilda MaibachSenior Vice President of Statistics

Latest SEC Filings

DateTypeTitle
Jun 23, 20258-KCurrent Report
Jun 20, 20258-KCurrent Report
May 13, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
May 12, 2025SCHEDULE 13G/AFiling
May 1, 2025ARSFiling
May 1, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2025DEF 14AOther definitive proxy statements
Mar 27, 20258-KCurrent Report
Mar 21, 202510-KAnnual Report